75695-93-1 Usage
Description
Isradipine, also known as 4-(4-benzofuranazyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester, is a second-generation dihydropyridine-type calcium channel blocker. It is more selective for vascular smooth muscle than for myocardial tissue and is effective in treating stable angina, reducing the frequency of anginal attacks, and the need to use nitroglycerin. Isradipine is also a long-acting calcium blocker effective in the treatment of essential hypertension, with advantages such as a "gentle" onset and fewer contraindications. It can be taken by patients with diabetes mellitus, chronic obstructive airway diseases, gout, congestive heart failure, or ischemic heart disease. It is a yellow solid and is available under the brand names DynaCirc and Prescal.
Uses
Used in Cardiovascular Applications:
Isradipine is used as an antihypertensive and antianginal agent for the treatment of essential hypertension and stable angina. It helps in reducing the frequency of anginal attacks and the need to use nitroglycerin.
Used in Neuroprotection:
Isradipine is used as a neuroprotective agent in a rat model of focal ischemia, providing a dose-dependent sparing of dopamine neuronal fibers and cell bodies.
Used in Anti-atherosclerotic Applications:
Isradipine is used for its anti-atherosclerotic effects in animals and for improving endothelium-mediated nitric oxide (NO)-dependent vasodilation in vitro.
Used in Non-sedating H1-antihistamine Applications:
Isradipine is used as a non-sedating H1-antihistamine, which may have potential applications in treating allergic reactions with minimal sedative effects.
Originator
Sandoz (Switzerland)
Biological Activity
Potent and selective L-type voltage-gated Ca 2+ channel blocker. EC 50 and pA 2 values are 1.4 nM and 10.3 for relaxation of depolarization- and Ca 2+ -induced contractions of rabbit aorta respectively; EC 25 = 0.45 nM for reduction in rate of spontaneously beating guinea pig right atria. Long-acting antihypertensive agent in vivo , exerting primary effects on vascular tissue with secondary negative chronotropic action.
Biochem/physiol Actions
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
References
1) Bracht et al. (2001), Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia; J. Hyperten., 19 899
2) Chandra et al. (1999), Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia ; Pharmacology, 58 292
3) Merck 14:5240
Check Digit Verification of cas no
The CAS Registry Mumber 75695-93-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,6,9 and 5 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 75695-93:
(7*7)+(6*5)+(5*6)+(4*9)+(3*5)+(2*9)+(1*3)=181
181 % 10 = 1
So 75695-93-1 is a valid CAS Registry Number.
InChI:InChI=1/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
75695-93-1Relevant articles and documents
THERAPY FOR COMPLICATIONS OF DIABETES
-
, (2009/07/02)
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
AN IMPROVED PROCESS FOR THE MANUFACTURE OF ISRADIPINE.
-
Page/Page column 7-9, (2008/06/13)
The present invention relates to an improved method for the manufacture of Isradipine, 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester. which, involves reacting 2,1,3-benzoxadiazole-4-carboxaldehyde with methyl acetoacetate in the presence of acetic acid and piperidine in diisopropyl ether. To obtain the product 2-acetyl-3-benzofurazan-4-yl-acrylic acid methyl ester which is then reacted with isopropyl-?-aminocrotonate in ethanol at 25 to 35°C to obtain the product.